Pharmacokinetic strategies for treatment of drug overdose and addiction

Future Medicinal Chemistry

Volumn 4, Issue 2, 2012, Pages 227-243

  Gorelick, David A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Antibodies that are all specific for the same antigen because they are made by identical immune cells that are clones of the same parent cell

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; ANTIBODY; CARBOXYLESTERASE; CATALYTIC ANTIBODY; CHOLINESTERASE; COCAINE; COTININE; DRUG METABOLITE; DRUGS USED IN THE TREATMENT OF ADDICTION; ESTERASE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; NIC 002; NICCINE; NICOTINE VACCINE; PHENCYCLIDINE; TA CD; TA NIC; UNCLASSIFIED DRUG; VACCINE;

ACUTE TOXICITY; ANTIBODY TITER; DRUG ABUSE; DRUG BINDING; DRUG CONCENTRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; GENETIC VARIABILITY; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PASSIVE IMMUNIZATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHODOCOCCUS; TOBACCO DEPENDENCE;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; OVERDOSE; PHARMACOKINETICS; SUBSTANCE-RELATED DISORDERS;

EID: 84856854307     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.190     Document Type: Review

References (80)

1. Steketee JD, Kalivas PW. Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacol. Rev. 63, 348-365 (2011).
2. Nelson RA, Boyd SJ, Ziegelstein RC et al. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend. 82, 19-24 (2006). (Pubitemid 43289100)
3. Ray R, Schnoll RA, Lerman C. Pharmacogenetics and smoking cessation with nicotine replacement therapy. CNS Drugs 21, 525-533 (2007). (Pubitemid 46984855)
4. Gorelick A. Pharmacokinetic approaches to treatment of drug addiction. Expert Rev. Clin. Pharmacol. 1, 277-290 (2008).
5. Moreno AY, Janda KD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol. Biochem. Behav. 92, 199-205 (2009).
6. de Villiers SH, Lindblom N, Kalayanov G et al. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 28, 2161-2168 (2010).
7. Ino A, Dickerson TJ, Janda KD. Positional linker effects in haptens for cocaine immunopharmacotherapy. Bioorg. Med. Chem. Lett. 17, 4280-4283 (2007). (Pubitemid 47021394)
8. Moreno AY, Mayorov AV, Janda KD. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J. Am. Chem. Soc. 133, 6587-6595 (2011).
9. Moreno AY, Azar MR, Warren NA, Dickerson TJ, Koob GF, Janda KD. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol. Pharm. 7, 431-441 (2010).
10. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR. The future of vaccines in the management of addictive disorders. Curr. Psychiatry Rep. 9, 381-387 (2007). (Pubitemid 47559359)
11. O'Leary K, Parameswaran N, McIntosh JM, Quik M. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. J. Pharmacol. Exp. Ther. 325, 646-654 (2008). (Pubitemid 351574817)
12. Buccafusco JJ, Beach JW, Terry AV Jr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J. Pharmacol. Exp. Ther. 328, 364-370 (2009).
13. Xu Y, Hixon MS, Yamamoto N et al. Antibody-catalyzed anaerobic destruction of methamphetamine. Proc. Natl Acad. Sci. USA 104, 3681-3686 (2007). (Pubitemid 47181515)
14. Nieri P, Donadio E, Rossi S, Adinolfi B, Podesta A. Antibodies for therapeutic uses and the evolution of biotechniques. Curr. Med. Chem. 16, 753-779 (2009).
15. Stitzer ML, Polk T, Bowles S, Kosten T. Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend. 107, 76-79 (2010).
16. Gentry WB, Ruedi-Bettschen D, Owens SM. Anti(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin. Pharmacol. Ther. 88, 390-393 (2010).
17. Treweek JB, Roberts AJ, Janda KD. Immunopharmacotherapeutic manifolds and modulation of cocaine overdose. Pharmacol. Biochem. Behav. 98, 474-484 (2011).
18. Cornish KE, Harris AC, LeSage MG et al. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int. Immunopharmacol. 11(11), 1809-1815 (2011).
19. Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem. Biol. Interact. 187, 421-424 (2010).
20. Heading CE. Drug evaluation: CYT-002- NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Curr. Opin Investig. Drugs 8, 71-77 (2007). (Pubitemid 46442205)
21. Cornuz J, Zwahlen S, Jungi WF et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3, e2547 (2008).
22. Hatsukami DK, Jorenby DE, Gonzales D et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 89, 392-399 (2011).
23. McNeil C. Nicotine vaccines move toward pivotal trials. J. Natl Cancer Inst. 98, 301 (2006).
24. Polosa R, Benowitz NL. Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol. Sci. 32, 281-289 (2011).
25. Escobar-Chavez JJ, Dominguez-Delgado CL, Rodriguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Des. Devel. Ther. 5, 211-224 (2011).
26. Oliver JL, Pashmi G, Barnett P et al. Development of an anticotinine vaccine to potentiate nicotine-based smoking cessation strategies. Vaccine 25, 7354-7362 (2007). (Pubitemid 47484018)
27. Martell BA, Orson FM, Poling J et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 66, 1116-1123 (2009).
28. Shorter DI, Lindsay JA, Springer JR, Kosten TR. The impact of cocaine vaccine (TA-CD) on opiate use in methadone-maintained, opiate- and cocaine-dependent participants. Presented at: College on Problems of Drug Dependence 73rd Annual Meeting. Hollywood, FL, USA (2011).
29. Mulpur S, Lindsay J, Kosten T. Gender differences in methadone-maintained cocaine users. Presented at: College on Problems of Drug Dependence 73rd Annual Meeting. Hollywood, FL, USA (2011).
30. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 67, 59-65 (2010).
31. Martinez D, Haney M, Foltin R et al. The use of PET to assess a vaccine for cocaine dependence. Presented at: College on Problems of Drug Dependence Annual Meeting. Quebec City, Canada (2007).
32. Hicks MJ, De BP, Rosenberg JB et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther. 19, 612-619 (2011).
33. Keyler DE, Roiko SA, Benlhabib E et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab. Dispos. 33, 1056-1061 (2005). (Pubitemid 41002789)
34. Carroll FI, Blough BE, Pidaparthi RR et al. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J. Med. Chem. 54, 5221-5228 (2011).
35. Duryee MJ, Bevins RA, Reichel CM et al. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 27, 2981-2988 (2009).
36. Kinsey BM, Jackson DC, Orson FM. Antidrug vaccines to treat substance abuse. Immunol. Cell Biol. 87, 309-314 (2009).
37. Anton B, Salazar A, Flores A et al. Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum. Vaccin. 5, 214-229 (2009).
38. Shen X, Kosten TA, Lopez AY et al. Morphine vaccination and its inhibition of morphine-induced CPP and analgesia in rats. Presented at: College on Problems of Drug Dependence 73rd Annual Meeting. Hollywood, FL, USA (2011).
39. Stowe GN, Vendruscolo LF, Edwards S et al. A vaccine strategy that induces protective immunity against heroin. J. Med. Chem. 54, 5195-5204 (2011).
40. Pravetoni M, LeNaour M, Portoghese PS, Raleigh M, Harmon T, Pentel PR. Development and immunological validation of an oxycodone conjugate vaccine in rats. Presented at: College on Problems of Drug Dependence 73rd Annual Meeting. Hollywood, FL, USA (2011).
41. Hrafnkelsdottir K, Valgeirsson J, Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol. Pharm. Bull. 28, 1038-1042 (2005). (Pubitemid 40880311)
42. Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J. 8, E383-E390 (2006). (Pubitemid 43840589)
43. Celikel R, Peterson EC, Owens SM, Varughese KI. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-methamphetamine and 3,4-methylenedioxymethamphetamine. Protein Sci. 18, 2336-2345 (2009).
44. Hu G, Chen LY. In silico experiments of single-chain antibody fragment against drugs of abuse. Biophys. Chem. 153, 97-103 (2010).
45. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res. 61, 108-120 (2004). (Pubitemid 39043717)
46. Norman AB, Norman MK, Buesing WR, Tabet MR, Tsibulsky VL, Ball WJ. The effect of a chimeric human/murine anticocaine monoclonal antibody on cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 328, 873-881 (2009).
47. Gentry WB, Ruedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum. Vaccin. 5, 206-213 (2009).
48. Treweek JB, Sun C, Mayorov AV et al. Prevention of drug-induced memory impairment by immunopharmacotherapy. J. Med. Chem. 51, 6866-6875 (2008).
49. Dickerson TJ, Janda KD. Recent advances for the treatment of cocaine abuse: central nervous system immunopharmacotherapy. AAPS J. 7, E579-E586 (2005).
50. Stephens BG, Jentzen JM, Karch S, Mash DC, Wetli CV. Criteria for the interpretation of cocaine levels in human biological samples and their relation to the cause of death. Am. J. Forensic Med. Pathol. 25, 1-10 (2004). (Pubitemid 38252580)
51. Owens M. Making effective and safe antibody medications for treating phencyclidine and methamphetamine addiction. Presented at: College on Problems of Drug Dependence annual meeting. Quebec City, Canada (2007).
52. Hatfield MJ, Tsurkan L, Hyatt JL et al. Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. Br. J. Pharmacol. 160, 1916-1928 (2010).
53. Duysen EG, Lockridge O. Prolonged toxic effects after cocaine challenge in butyrylcholinesterase/plasma carboxylesterase double knockout mice: a model for butyrylcholinesterase-deficient humans. Drug Metab. Dispos. 39, 1321-1323 (2011).
54. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. 48, 159-165 (1997). (Pubitemid 27526022)
55. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem. Biol. Interact. 175, 83-87 (2008).
56. Xue L, Ko MC, Tong M et al. Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol. Pharmacol. 79, 290-297 (2011).
57. Brimijoin S, Gao Y, Anker JJ et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33, 2715-2725 (2008).
58. Carroll ME, Gao Y, Brimijoin S, Anker JJ. Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology 213, 817-829 (2011).
59. Godin CS, Shemesh-Darvish L, Sklair-Tavron L, Rosenstock M. TV-1380 (Albumin-Fused Mutated BChE) Attenuates the Cardiovascular and Respiratory Effects Induced by Cocaine in Cynomolgus Monkeys. Avanza Laboratories, Gaithersberg, MD, USA (2011).
60. Schindler CW, Justinova Z, Lafleur D et al. Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. Addict. Biol. In Press (2012).
61. Gao D, Narasimhan DL, Macdonald J et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol. Pharmacol. 75, 318-323 (2009).
62. Ko MC, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Woods JH. Effects of cocaine esterase following its repeated administration with cocaine in mice. Drug Alcohol Depend. 101, 202-209 (2009).
63. Wood SK, Narasimhan D, Cooper Z, Sunahara RK, Woods JH. Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend. 106, 219-229 (2010).
64. Jutkiewicz EM, Baladi MG, Cooper ZD, Narasimhan D, Sunahara RK, Woods JH. A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann. Emerg. Med. 54, 409-420 (2009).
65. Huang X, Gao D, Zhan CG. Computational design of a thermostable mutant of cocaine esterase via molecular dynamics simulations. Org. Biomol. Chem. 9, 4138-4143 (2011).
66. Collins GT, Brim RL, Narasimhan D et al. Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J. Pharmacol. Exp. Ther. 331, 445-455 (2009).
67. Collins GT, Carey KA, Narasimhan D et al. Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology 36, 1047-1059 (2011).
68. Collins GT, Brim RL, Narasimhan D et al. Repeated administration of a mutant cocaine esterase: Effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys. Presented at: College on Problems of Drug Dependence, 73rd annual meeting. Hollywood, FL, USA (2011).
69. Park JB, Kwon YM, Lee TY et al. PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J. Control Release 142, 174-179 (2010).
70. Zheng F, Zhan CG. Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction. Org. Biomol. Chem. 6, 836-843 (2008). (Pubitemid 351653352)
71. McKenzie KM, Mee JM, Rogers CJ, Hixon MS, Kaufmann GF, Janda KD. Identification and characterization of single chain anticocaine catalytic antibodies. J. Mol. Biol. 365, 722-731 (2007). (Pubitemid 44960359)
72. Finkle BS, McCloskey KL. The forensic toxicology of cocaine (1971-1976). J. Forensic Sci. 23, 173-189 (1978).
73. Lockridge O, Schopfer LM, Winger G, Woods JH. Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity. J. Med. Chem. Biol. Radiol. Def. 3, nihms5095 (2005).
74. Li S, Ip DT, Lin HQ et al. High-level expression of functional recombinant human butyrylcholinesterase in silkworm larvae by Bac-to-Bac system. Chem. Biol. Interact. 187, 101-105 (2010).
75. Podoly E, Bruck T, Diamant S et al. Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener. Dis. 5, 232-236 (2008). (Pubitemid 351347859)
76. Anker JJ. Long-term blockade of cocaine seeking in rats treated with a cocaine hydrolase viral vector. Presented at: College on Problems of Drug Dependence 73rd Annual Meeting. Hollywood, FL, USA (2011).
77. Chilukuri N, Duysen EG, Parikh K et al. Adenovirus-mediated gene transfer of human butyrylcholinesterase results in persistent high-level transgene expression in vivo. Chem. Biol. Interact. 175, 327-331 (2008).
78. Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum - A hydrolase gene therapy approach. J. Pharmacol. Exp. Ther. 330, 449-457 (2009).
79. Rogers CJ, Eubanks LM, Dickerson TJ, Janda KD. Unexpected acetylcholinesterase activity of cocaine esterases. J. Am. Chem. Soc. 128, 15364-15365 (2006). (Pubitemid 44875999)
80. Hall W, Gartner C. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Curr. Opin Psychiatry 24, 191-196 (2011).